104 related articles for article (PubMed ID: 2145254)
1. Microbiological and pharmacokinetic studies of acyl demycinosyltylosin and related tylosin derivatives.
Cacciapuoti AF; Loebenberg D; Moss EL; Menzel FW; Rudeen JA; Naples LR; Cramer CL; Hare RS; Mallams AK; Miller GH
J Antibiot (Tokyo); 1990 Sep; 43(9):1131-6. PubMed ID: 2145254
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies on 4''-O-acyltylosin derivatives: significance of their 23-O-mycinosyl and 4''-O-acyl moieties in antimicrobial activity against macrolide-resistant microbes.
Kiyoshima K; Sakamoto M; Nomura H; Yoshioka T; Okamoto R; Sawa T; Naganawa H; Takeuchi T
J Antibiot (Tokyo); 1989 Nov; 42(11):1661-72. PubMed ID: 2584151
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of novel 8-methoxy derivatives of chlortetracycline.
Cacciapuoti A; Moss EL; Menzel F; Cramer CA; Weiss W; Loebenberg D; Hare RS; Miller GH
J Antibiot (Tokyo); 1987 Oct; 40(10):1426-30. PubMed ID: 3680008
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of the new oral macrolide azithromycin.
Neu HC; Chin NX; Saha G; Labthavikul P
Eur J Clin Microbiol Infect Dis; 1988 Aug; 7(4):541-4. PubMed ID: 2846300
[TBL] [Abstract][Full Text] [Related]
5. Sporeamicin A, a new macrolide antibiotic. III. Biological properties.
Morishita A; Mutoh N; Ishizawa K; Suzuki T; Yokoiyama S; Yaginuma S
J Antibiot (Tokyo); 1992 May; 45(5):613-7. PubMed ID: 1624362
[TBL] [Abstract][Full Text] [Related]
6. Comparative erythromycin and tylosin susceptibility testing of streptococci from bovine mastitis.
Entorf M; Feßler AT; Kaspar H; Kadlec K; Peters T; Schwarz S
Vet Microbiol; 2016 Oct; 194():36-42. PubMed ID: 26732695
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity and in vivo efficacy of a new series of 9-deoxo-12-deoxy-9,12-epoxyerythromycin A derivatives.
Hardy DJ; Swanson RN; Shipkowitz NL; Freiberg LA; Lartey PA; Clement JJ
Antimicrob Agents Chemother; 1991 May; 35(5):922-8. PubMed ID: 1854173
[TBL] [Abstract][Full Text] [Related]
8. Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues.
Griesgraber G; Kramer MJ; Elliott RL; Nilius AM; Ewing PJ; Raney PM; Bui MH; Flamm RK; Chu DT; Plattner JJ; Or YS
J Med Chem; 1998 May; 41(10):1660-70. PubMed ID: 9572891
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin.
Gill CJ; Abruzzo GK; Flattery AM; Smith JG; Jackson J; Kong L; Wilkening R; Shankaran K; Kropp H; Bartizal K
J Antibiot (Tokyo); 1995 Oct; 48(10):1141-7. PubMed ID: 7490222
[TBL] [Abstract][Full Text] [Related]
10. Chemical modification of erythromycins. III. In vitro and in vivo antibacterial activities of new semisynthetic 6-O-methylerythromycins A, TE-031 (clarithromycin) and TE-032.
Morimoto S; Nagate T; Sugita K; Ono T; Numata K; Miyachi J; Misawa Y; Yamada K; Omura S
J Antibiot (Tokyo); 1990 Mar; 43(3):295-305. PubMed ID: 2139023
[TBL] [Abstract][Full Text] [Related]
11. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).
Hanson CW; Bailer R; Gade E; Rode RA; Fernandes PB
J Clin Microbiol; 1987 Jun; 25(6):1079-82. PubMed ID: 2954995
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
Logan MN; Ashby JP; Andrews JM; Wise R
J Antimicrob Chemother; 1991 Feb; 27(2):161-70. PubMed ID: 1829073
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
Peters DH; Clissold SP
Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
[TBL] [Abstract][Full Text] [Related]
14. The in-vitro activity of CP-62,993 against Haemophilus influenzae, Branhamella catarrhalis, staphylococci and streptococci.
Dunkin KT; Jones S; Howard AJ
J Antimicrob Chemother; 1988 Apr; 21(4):405-11. PubMed ID: 2837451
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.
Dette GA; Knothe H; Koulen G
Drugs Exp Clin Res; 1987; 13(9):567-76. PubMed ID: 2962847
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.
Tanikawa T; Asaka T; Kashimura M; Suzuki K; Sugiyama H; Sato M; Kameo K; Morimoto S; Nishida A
J Med Chem; 2003 Jun; 46(13):2706-15. PubMed ID: 12801234
[TBL] [Abstract][Full Text] [Related]
17. [In vitro antibacterial activity of clarithromycin, a new macrolide antibiotic, and regression curve].
Soussy CJ; Le Van Thoi J; Cluzel M; Derlot E; Kitzis MD
Pathol Biol (Paris); 1990 May; 38(5):401-6. PubMed ID: 2142274
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antibacterial activity of acylides (3-O-acyl-erythromycin derivatives): a novel class of macrolide antibiotics.
Tanikawa T; Asaka T; Kashimura M; Misawa Y; Suzuki K; Sato M; Kameo K; Morimoto S; Nishida A
J Med Chem; 2001 Nov; 44(24):4027-30. PubMed ID: 11708904
[TBL] [Abstract][Full Text] [Related]
19. Effect of dosing intervals on efficacy of clarithromycin and erythromycin in mouse infection models.
Fernandes PB; Swanson RN; Hardy DJ; McDonald EJ; Ramer N
Drugs Exp Clin Res; 1988; 14(7):441-4. PubMed ID: 2977115
[TBL] [Abstract][Full Text] [Related]
20. Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues.
Elliott RL; Pireh D; Griesgraber G; Nilius AM; Ewing PJ; Bui MH; Raney PM; Flamm RK; Kim K; Henry RF; Chu DT; Plattner JJ; Or YS
J Med Chem; 1998 May; 41(10):1651-9. PubMed ID: 9572890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
